Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.75 |
| ▸ | PLG | P00747 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19296386 | 0.93 | FOLH1 (0.77) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26090338 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29679477 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29679057 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL28659047 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL23553003 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL21310703 | 0.93 | FOLH1 (0.82) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL19296389 | 0.93 | FOLH1 (0.76) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL26178698 | 0.92 | FOLH1 (0.78) | FOLH1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL27303660 | 0.92 | FOLH1 (0.73) | FOLH1PLGPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008232-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008232-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS FOR TARGETING PROSTATE CANCER | KLK3, MAN2B2, BPHL | FOLH1 9/4885PLG 2131/4885PRSS1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.